Lung highlights from ESMO 2018

Click here to view original web page at

Dr Capuzzo speaks with ecancer at ESMO 2018 in Munich about results from lung cancer trials reported at the conference.

He reports a confirmed survival benefit in the PACIFIC trial for patients with high and medium PD-L1 expression, and negative results from a second-line study of atezolizumab in small cell lung cancer, as discussed by Dr Jean-Louis Pujol.

Dr Capuzzo also spoke with ecancer about the IMpower130 study of atezolizumab as first-line NSCLC therapy.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.